Locations:
Min Investment:
Max Investment:
Target Investment:
2019
2011
2011
Strategy by Design- We work with exceptional startups and help them in their drive to success. Navigating a company from conception to exit is difficult and fraught with pitfalls. We help companies to stay on the road to growth and exit. -Startup Business Plans -Funding Strategy -Investor Outreach
2012
2011
2011
2017
Walter Greenblatt & Associates Bridging the Gap Between Science and Investment Walter Greenblatt & Associates is a lifescience-focused boutique investment bank. Our clients are early-stage biotechnology, medical device, diagnostics and pharmaceutical service companies. WG&A works with clients to define and articulate strategy and then translates clients' science and technology into the language of business so investors can understand the economic value proposition. We call this sleeves-rolled-up approach Full-Contact Investment Banking™. Since inception, the firm has raised $99 million in seed, Series A and Series B funding rounds for early stage lifescience companies and returned over $615 million to the investors in those rounds with several of the companies still driving towards promising liquidity events that would increase that return. We are always looking for great lifescience companies and the people who want to invest in them.
2013 - 2017
2013 - 2017
NovoBioPharma is a partnership of experts collaborating with life science organizations to provide comprehensive medical, scientific, regulatory, business and financial advisory services. This global partnership works with life science companies and institutions to cost-efficiently advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development, and ultimately, regulatory approval. With decades of experience and a global network in all areas of business, finance, drug, diagnostic and device development, NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design, and protocol development. Simply put, NovoBioPharma covers every facet of the risky and costly work of developing life science breakthroughs.
2011 - 2016
2011 - 2016
CapGenic works with mid-market through early stage companies to bring value through merger and acquisition intermediation, corporate development, alliance building and capital formation, with a focus on analysis, formulation, refinement, and implementation of successful business strategies.In his role at CapGenic Ira has worked across industries from pharmaceuticals and healthcare IT to manufacturing to entertainment and television.
2004 - 2010
2004 - 2010
Founded and funded EyeIC , a software base medical device company. Landed funding and lead the company through FDA 510k and new CPT processes. • Capital Formation • Corporate Strategy • Medical Devices • FDA • Medical Payment system • KOL management • Software development
2002 - 2004
2002 - 2004
Identified medical opportunities for Penn discoveries. Licensing and Intellectual Property Management
2003 - 2004
2003 - 2004
Responsible for the commercialization of ophthalmology opportunities for Sarnoff's computer vision technologies